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Summary Expression of c-myc was studied immunohistochemically in 100 colorectal carcinomas, using a
monoclonal antibody, Myc 1-6E10, which is purported to recognize the oncoprotein (p62c-'Yc) in paraffin-
embedded material. In normal epithelium, maturing crypt cells and terminally differentiated surface cells were
positive, and proliferating basal crypt cells negative. All carcinomas stained positively, but intensity was
independent of histological differentiation, Dukes' stage, DNA ploidy and survival. Staining was
predominantly cytoplasmic despite the suspected nuclear location of p62c-mYc and there was considerable
staining of fibroblasts. When staining was compared in frozen and paraffin-embedded sections fixed in
different ways, different patterns were observed. Acetone-fixed frozen sections exhibited weak nuclear and
cytoplasmic staining or were negative. In formol-saline fixed frozen sections, there was stronger
predominantly nuclear staining. In paraffin-embedded sections staining was predominantly cytoplasmic. This
study suggests that c-myc expression is enhanced in the majority of colorectal carcinomas and although
independent of clinical behaviour, may be a common event in malignant transformation. However, since
staining is affected by fixation and processing, data obtained using Myc 1-6E10 on routinely processed
specimens should be interpreted with caution.
At least 40 viral and cellular oncogenes and proto-oncogenes
have been identified (Bishop, 1985; Weinberg, 1985;
Barbacid, 1986). Proto-oncogenes are normal cellular genes
which are present in all cells and involved in the regulation
of proliferation and differentiation. They may become
converted to oncogenes by point mutation, chromosomal
rearrangement or amplification. However, the precise
functions of these genes in normal and neoplastic cells are
uncertain.
The c-myc oncogene encodes for a 62,000 molecular
weight protein product, p62c-mYc (Alitalo et al., 1983; Hann &
Eisenman, 1984), which is predominantly located in the
nucleus (Eisenman et al., 1985; Evan & Hancock, 1985) and
thought to be involved in the regulation of cellular
proliferation. A definitive role for the oncoprotein has not
been elucidated; however, the cellular homologues of the
c-myc gene are highly conserved across species suggesting
that it is of considerable functional importance. There is a
background level of c-myc expression which increases when
quiescent cells are stimulated to proliferate and decreases
with terminal differentiation. Expression of the c-myc gene is
regulated at both transcriptional and post-transcriptional
levels (reviewed in; Cole, 1986; Eisenman & Thompson,
1986; Alitalo et al., 1987).
The c-myc locus is situated on the long arm of
chromosome 8 and is commonly involved in the genetic
alterations of malignancy. In Burkitt's lymphoma the
segment of chromosome 8 carrying the c-myc locus is
commonly translocated to chromosome 14 and less
commonly to either chromosome 2 or 22. The c-myc locus is
juxtaposed to an immunoglobulin locus which is extremely
active in B lymphocytes due to chronic Epstein-Barr virus
exposure. This may result in deregulation and inappropriate
expression of the c-myc gene; a phenomenon of potential
importance in the pathogenesis of B cell lymphoma
(reviewed in; Klein & Klein, 1985; Cole, 1986).
Elevated levels of c-myc mRNA and p62c-myc have been
detected in cell lines and solid tumours using molecular
biological techniques. Meltzer et al. (1987) found c-myc
amplification in 3 out of 45 colonic carcinomas; Sikora et al.
(1987) studied 15 colorectal cancers and found neither
amplification nor rearrangement, although elevated levels of
c-myc mRNA were detected in 12 cases.
The study of oncogene expression has been potentially
facilitated by the recent development of monoclonal
antibodies to oncoproteins. These reagents are easily applied
to tissue sections and qualitative information obtained on
the cellular distribution of the oncoprotein. Quantitative
data are however, less readily acquired.
The sequence of nucleotides of the c-myc gene has been
identified and p62c-myc deduced to be a 439 amino acid
product. Hydrophilic portions of the protein theoretically lie
on the external surface of the molecule and are therefore
potentially antigenic. Synthetic peptide fragments have been
constructed corresponding to these regions and used as
immunogens to raise monoclonal antibodies which recognize
the intact oncoprotein (Evan et al., 1985). An 18 amino acid
peptide fragment corresponding to residues 171-188 was
used to raise a mouse monoclonal antibody Myc 1-6E10.
This antibody immunoprecipitates a 62-kD protein from cell
lysates and specifically binds to a 62-kD protein in electro-
blotted cell extracts. A 62-kD protein of identical mobility is
recognized by a polyclonal rabbit antibody which recognizes
the human c-myc gene product (Evan et al., 1985). Myc
1-6E10 is also claimed to recognize p62c-mYc in routinely
processed paraffin-embedded specimens (Sikora et al., 1985).
In this study Myc 1-6E10 has been used to assess c-myc
oncogene expression in colorectal cancer.
Materials and methods
The main study group consisted of 100 patients presenting
with colorectal cancer between 1981 and 1983. All have been
prospectively followed for three years. Normal mucosa was
obtained from the most distant resection margin of 22 recent
cases and from 10 patients with irradiation bowel disease.
Myc 1-6E10 (Evan et al., 1985) was obtained from Prof.
K. Sikora and following titration, used at a concentration of
1:500 in Tris buffered saline (TBS).
Paraffin-embedded tissue sections were stained using a
three step immunoperoxidase technique. Sections (4pum) were
dewaxed in xylene, rehydrated through a series of ethanols,
and endogenous peroxidase activity blocked using 0.5%
hydrogen peroxide in methanol for 20min. Sections were
then incubated with the primary mouse monoclonal antibody
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for 60min, and subsequently with peroxidase conjugated
rabbit anti-mouse and peroxidase conjugated swine anti-
rabbit sera, each for 30min. Slides were washed in TBS
between each incubation step. The peroxidase reaction was
developed using diaminobenzidine in TBS (0.6mgml-1)
containing fresh hydrogen peroxide (0.01%), producing a
brown stain in areas of antibody binding. Sections were
washed in tap water, counterstained with Mayer's
haematoxylin, dehydrated, cleared and mounted under DPX.
Negative controls (TBS instead of Myc 1-6E10) were
included for each case and a positive control for each batch.
In a further 20 cases staining patterns were compared in
(a) air dried cryostat sections, fixed in acetone for 10min, (b)
air dried cryostat sections fixed in formol-saline for 48h, and
(c) routinely processed formol-saline fixed paraffin-embedded
sections.
The SW620 colorectal adenocarcinoma cell line (Leibowitz
et al., 1976) was grown as a monolayer on glass slides.
Staining was compared following acetone and formol-saline
fixation.
Staining patterns were assessed independently by two
observers (DJJ and AKG) with regard to distribution,
subcellular location and intensity using a three point scoring
system.
DNA ploidy status was determined by flow cytometry
(reported in detail elsewhere, Jones et al., 1988) using
adjacent 30gm paraffin-embedded sections using the method
of Hedley et al. (1983).
Statistical comparison of staining intensity and patho-
logical features was by Chi squared analysis.
Results
The assessment of immunohistochemical staining is to some
extent subjective, but there was 90% initial agreement
between the two observers, and similar clinical and patho-
logical correlations taking each assesment independently.
Paraffin-embedded sections
A similar staining pattern was observed in normal mucosa
obtained from patients with and without large bowel
neoplasia; maturing crypt cells and surface epithelial cells
exhibited weak staining and proliferating basal cells were
negative (Figure 1).
All 100 carcinomas stained positively but with varying
distribution and intensity; staining was uniform in 51 (Figure
2) and patchy in 49 (Figure 3).
Twenty-nine stained weakly, 42 moderately and 29
strongly. Similar staining patterns were observed for.
different histological grades (Table I) and Dukes' stage
(Table II).
Thirty-six were DNA diploid and 64 DNA aneuploid.
DNA ploidy status was independent of staining pattern
(Table III).
The prognosis was similar for each sub-group; 52% of
patients with weak, 45% with moderate and 48% with
strong staining survived three years.
In both normal and neoplastic tissue staining was
predominantly cytoplasmic (Figures 1 and 2), although in 6
carcinomas moderate nuclear staining was observed (Figure
4). There was also moderate staining of stromal elements
and smooth muscle (Figures 1 and 2).
Effects offixation on staining
Acetone fixed cryostat sections exhibited weak nuclear and
cytoplasmic staining or were negative. Adjacent sections
fixed in formol-saline exhibited stronger staining which was
both nuclear and cytoplasmic. Corresponding routinely
processed formol-saline fixed paraffin-embedded samples
revealed predominantly cytoplasmic staining.
Acetone fixed SW620 cells exhibited predominantly
nuclear staining (Figure 5). In formol-saline fixed SW620
cells, staining was predominantly cytoplasmic, being
strongest in mitotic cells (Figure 5).
Discussion
The development of monoclonal antibodies which specifically
recognize oncoproteins should theoretically facilitate the
study of oncogene expression in human tumour samples.
The p62cmYc gene product has hitherto been considered to
be predominantly nuclear in cellular location (Eisenman et
al., 1985; Evan & Hancock, 1985). C-myc expression
increases when quiescent GO cells are stimulated to
proliferate and decreases with terminal differentiation
(reviewed in; Eisenman & Thompson, 1986; Cole, 1986;
Alitalo et al., 1987). However, the precise role of p62c-myc is
not known.
In the present study immunohistochemical staining for
p62C-mYc was predominantly cytoplasmic in paraffin-
embedded sections. Normal maturing and differentiated
mucosal cells were positive yet proliferating basal crypt cells
were negative. There was also considerable staining of
fibroblasts. The results suggest that c-myc expression is
increased in the majority of colorectal carcinomas and
although unrelated to tumour behaviour could be a common
event in malignant transformation.
Stewart et al. (1986) also used Myc 1-6E10 on normal and
neoplastic colorectal epithelium and observed similar staining
patterns. In carcinomas staining intensity was greatest in well
differentiated tumours and decreased with decreasing histo-
logical differentiation. By contrast, Ciclitira et al. (1987)
reported different staining patterns with this antibody.
Normal colonic epithelium was negative apart from some
very weak staining of occasional superficial enterocytes.
Table I Staining intensity compared
histological differentiation
to
Intensity Well Moderate Poor
+ 11 14 4
+-+ 9 25 8
+++ 6 20 3
Total 26 59 15
x2=4.2, 4df, P=0.38.
Table II Dukes' stage compared to staining
intensity (97 patients)
Intensity A B C
+ 4 12 11
++ 4 23 14
+++ 1 11 17
Total 9 46 42
x2=5.62, 4df, P=0.22.
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Figure 1 Normal colonic epithelium stained with Myc 1-6E10
showing weak cytoplasmic staining of maturing crypt cells and
surface epithelial cells. ( x 80)
Figure 3 Carcinoma of colon stained with Myc 1-6E10 showing
heterogeneous staining. ( x 80)
Figure 2 Carcinoma of the colon stained with Myc 1-6E10
showing uniform staining. ( x 80)
Figure 4 Nuclear and cytoplasmic staining with Myc 1-6E10.
( x 190)
Figure 5 Myc 1-6E10 staining of SW620 colorectal adenocarcinoma cell line: (left) acetone fixed for 10 min, showing
predominantly nuclear staining; (right) formol-saline fixed, showing absence of nuclear staining, but cytoplasmic staining, strongest
in mitotic cells. ( x 240).
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Positive staining was observed in inflammatory bowel disease
especially in association with marked lymphocytic infiltration
and dysplastic change.
Cytoplasmic disperson of p62c-mYc with other nuclear
components occurs during mitosis (Eisenman et al., 1985)
and is demonstrated in this study by stronger staining in
mitotic SW260 cells. However, cytoplasmic staining was also
prominent in non-proliferating cells. The oncoprotein is
extracted from the nucleus by mild salt concentrations and
by fixation (Evan & Hancock, 1985; Stewart et al., 1986). It
is also suggested that redistribution of the protein to the
cytoplasm could occur during maturation and differentiation
(Hendy-Ibbs et al., 1987). The results in the present study
show that the observed staining patterns are largely a
function of processing rather than a biological phenomenon.
Since acetone fixed cryostat sections were only weakly
positive or negative, formol-saline fixation presumably either
'unmasks' or modifies the protein recognized by Myc 1-6E10
so as to facilitate antibody binding. The differences between
formol-saline fixed cryostat sections and formol-saline fixed
paraffin-embedded sections may be due to differences in
tissue penetration of the fixative. Extensive staining of
differentiated cells including fibroblasts and smooth muscle,
could be due to cross reaction with proteins other than
p62c-mYc. Alternatively, the peptide fragment used to raise
Myc 1-6E10 may be common to other proteins or the anti-
body may bind to similar sequences in unrelated proteins.
Antibody binding could be blocked with the peptide
immunogen; however, this would inhibit non-specific as well
as specific staining.
Jack et al. (1986) studied c-myc expression in malignant
lymphomas using Myc 1-6E10. The p62c-mYc product was
predominantly cytoplasmic and widely distributed in normal
tissue, but was detected in only a minority of lymphomas. A
second antibody Myc 1-9E10, which recognizes a different
site on p62c-mYc gave similar staining patterns. This was
considered to militate against significant cross reactivity and
non-specific binding. On completion of the present study,
Myc 1-9E10 was acquired and found to give closely similar
staining patterns in our colorectal carcinomas. Sikora et al.
(1987) studied c-myc expression in 15 colorectal carcinomas
using molecular biological and immunocytochemical
techniques. There was close correlation between c-myc
mRNA copy number and p62c-mYc abundance, detected by
immunoblotting using Myc 1-6E10, mRNA levels were
greater in tumour compared to normal mucosa. Immuno-
histology of corresponding sections showed staining of low
intensity in normal maturing crypt cells. Carcinomas stained
strongly if well differentiated, but weakly if poorly
differentiated.
These studies are consistent with the protein recognized by
Myc 1-6E10 being p62c-mYc, but do not completely exclude
non-specific binding. Although staining patterns in routinely
processed specimens do not precisely reflect the in vivo
subcellular distribution of the oncoprotein, they may never-
theless be indicative of its distribution at the tissue level. If
so, then the oncoprotein has a more widespread distribution
and differing function than previously suspected.
Clarification of the significance of staining patterns is
therefore dependent on a greater understanding of the
function of p62c-mYc in normal and neoplastic cells.
In the present study DNA ploidy was determined by flow
cytometry using adjacent paraffin-embedded sections (see
also Jones et al., 1988). Enhanced expression of p62c-mYc was
a feature of both DNA diploid and DNA aneuploid tumours
suggesting that increased c-myc expression is a feature of
both minor and major chromosomal rearrangements. Flow
cytometric techniques have been developed for the
simultaneous measurement of p62c-mYc levels and DNA
content in nuclei extracted from paraffin-embedded material
(Watson et al., 1985) with somewhat inconsistent results. In
breast cancer, elevated levels of p62c-myc were associated with
poor prognostic factors (Dowle et al., 1987). Conversely in
testicular cancer decreasing levels were associated with
decreasing histological differentiation (Watson et al., 1986).
Normal cervical epithelium was found to have higher levels
than cervical carcinomas (Hendy-Ibbs et al., 1987). However,
when tissue sections were stained using Myc 1-6E10, normal
cervical epithelium was negative and carcinomas were
positive (Covington et al., 1987). In our view the cytoplasmic
staining observed with Myc 1-6E10 effectively precludes its
use in a flow cytometric technique that utilizes nuclei alone
and probably accounts for these inconsistent results.
Monoclonal antibodies have also been raised to ras gene
products. To date these have also proved to be of limited
value for the immunohistochemical detection of ras products.
This is due to non-specific binding, an inability to
distinguish normal from mutant ras products and normal
from neoplastic tissues (Ghosh et al., 1986; Robinson et al.,
1986; Carney et al., 1986).
If monoclonal antibodies to oncoproteins are to be used
on routinely processed specimens, there is clearly a need for
new reagents of greater specificity. Ideally the results
obtained with such antibodies should be evaluated with
comparative information from hybridisation and protein
extraction studies.
In conclusion, these data suggest that c-myc oncogene
expression is a feature of normal maturing and terminally
differentiated mucosal cells. Expression is increased to a
quantitatively indefinable extent in the majority of colorectal
carcinomas, but is unrelated to clinical behaviour. However,
in view of the paradoxical staining patterns, data obtained
using Myc 1-6E10 on routinely processed samples should be
interpreted with caution.
This study was supported by the North West Regional Health
Authority and the Cancer Research Campaign.
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